Epidemiology and Survival Outcomes for Patients With NSCLC in Scandinavia in the Preimmunotherapy Era: A SCAN-LEAF Retrospective Analysis From the I-O Optimise Initiative

doi:10.1016/j.jtocrr.2021.100165

JTO Clinical and Research Reports

Volume 2, Issue 5, May 2021, 100165

https://doi.org/10.1016/j.jtocrr.2021.100165 Get rights and content

Under a Creative Commons license

open access

Abstract

Introduction

SCAN-LEAF, part of the I-O Optimise initiative, is a retrospective, longitudinal study investigating the epidemiology, clinical care, and outcomes for patients with NSCLC in Scandinavia. We report overall survival (OS) trends for patients diagnosed with NSCLC in Sweden and Denmark between 2005 and 2015.

Methods

Swedish and Danish cohorts were established by linking national registries. Data on all adults diagnosed with incident NSCLC from January 1, 2005, to December 31, 2015, were included. For temporal analyses of OS trends, patients were stratified by TNM stage and histology.

Results

Between 2005 and 2015, a total of 30,067 and 31,939 patients from Sweden and Denmark, respectively, were diagnosed with NSCLC; the most common histological subtype was nonsquamous cell carcinoma (56.9% and 53.0%) and 48.4% and 51.6% were diagnosed at stage IV. Over the study period, significant improvements in short-term survival (1 y) were observed for patients with nonsquamous cell carcinoma in both countries, regardless of disease stage at diagnosis; however, improvements in longer-term survival (5 y) were limited to patients with stage I and II disease only. Conversely, among patients with squamous cell histology, improvements in short-term survival were only observed for stage I disease in Sweden and stage IIIA disease in Denmark, while significant improvements in longer-term survival were seen only for stage IIIA NSCLC in both countries.

Conclusions

Despite some survival improvements between 2005 and 2015, an unmet need remains for patients with advanced NSCLC, particularly those with squamous cell histology. Future analyses will evaluate the impact of newer treatments on OS in NSCLC.

Keywords

Epidemiology

Non–small cell lung cancer

Survival

I-O Optimise

Real-world data

Cited by (0)

: Disclosure: Dr. Ekman is employed by an institution that was remunerated by Bristol Myers Squibb for this study. Drs. Horvat, Rosenlund, Patel, and A.M. Kejs were employees of IQVIA at the time of this study. Drs. Juarez-Garcia, Daumont, and Penrod are employees of Bristol Myers Squibb. Drs. Juarez-Garcia and Penrod report having stock ownership in Bristol Myers Squibb. L. Lacoin is an employee of Epi-Fit and was contracted (paid) as a consultant by Bristol Myers Squibb to support the I-O Optimise initiative. Dr. Brustugun reports receiving honoraria from AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Pierre Fabre, Roche, and Takeda and research funding from Pfizer, AstraZeneca, Roche, GlaxoSmithKline, and Boehringer Ingelheim outside of the submitted work. Dr. Sørensen reports receiving honoraria for scientific contributions from Bristol Myers Squibb.